London
· Delayed Price · Currency is GBP · Price in GBX Faron Pharmaceuticals Oy Company Description
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company.
Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation.
The company is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
In addition, it develops receptors involved in regulation of immune response in organ damage and bone marrow regeneration.
Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
| Country | Finland |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Juho Jalkanen |
Contact Details
Address: Joukahaisenkatu 6 B Turku, 20520 Finland | |
| Phone | 358 2469 5151 |
| Website | faron.com |
Stock Details
| Ticker Symbol | FARN |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FI4000153309 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Juho Jalkanen | Chief Executive Officer |
| Yrjö Erik Wichmann | Chief Financial Officer |